Navigation Links
Three Expert Opinion Journals now Publishing Original Research
Date:2/26/2008

LONDON, February 26 /PRNewswire/ -- Expert Opinion provides systematic and authoritative analysis enabling the pharmaceutical community to access and track key developments that lead to the creation of new drugs. Expert Opinion on Pharmacotherapy, Expert Opinion on Biological Therapy and Expert Opinion on Therapeutic Targets are now accepting original research.

Why publish with Expert Opinion

All the Expert Opinion journals publish independent and authoritative peer-reviewed articles; provide efficient and effective editorial support through from submission to publication that can take as little as 8 - 12 weeks. The journals are indexed by all major databases, including: Medline, Current Contents and EMBASE.

About the journals

Expert Opinion on Pharmacotherapy provides comprehensive coverage of emerging literature on newly approved compounds and assesses the likely impact of these new agents on existing pharmacotherapy of specific diseases. Expert Opinion on Pharmacotherapy focuses on new drugs and classes from development Phase III to those that have been available to pharmacopoeia for up to five years. Impact Factor: 1.733

Expert Opinion on Biological Therapy covers all aspects of biological therapy, from therapeutic peptides and proteins to gene transfer technologies and drug delivery systems, placing new advances in the context of current therapeutic practice and providing an expert opinion on the scope for future development. Impact Factor: 2.705

Expert Opinion on Therapeutic Targets publishes in-depth reports and reviews of the latest developments in the field of drug target discovery and validation. The journal provides an essential link between basic research on biological pathways and interactions and the development of the drugs for tomorrow. It is distinguished from other publications by its high-quality authorship and expertly drafted articles, structured to incorporate the author's expertise on the subject. Impact Factor: 2.662

For more information, please contact:

Elizabeth Knowles

email: elizabeth.knowles@informa.com

Tel no: +44(0)20-7017-4742


'/>"/>
SOURCE Expert Opinion
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. KGI Elects Three New Members to Board of Trustees
2. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
3. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
4. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
5. European Union has Three-Speed Healthcare System - Many Countries Lagging in Reform
6. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
7. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
8. Pharmasset to Present at Three Investor Conferences in November 2007
9. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
10. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
11. Gen-Probe to Webcast Three Upcoming Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... BEIJING, Feb. 23, 2017 China Biologic Products, Inc. ... integrated plasma-based biopharmaceutical company in China, today announced its financial ... Fourth Quarter 2016 Financial Highlights ... increased by 21.7% in RMB terms, or increased by 13.6% ... the same quarter of 2015. Gross profit ...
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook Labs is ... include an array of biochemical analyses critical for Lead Discovery. The company’s ... and SAR programs, including inhibitor potency and selectivity, mechanism of action, and inhibitor ...
(Date:2/23/2017)... Feb. 23, 2017  Imanis Life Sciences announced ... of oncolytic vaccinia viruses for virotherapy research. These ... of Genelux,s proprietary, vaccinia virus-based technology platform for ... enter into a partnership with Genelux to offer ... viruses for use in research," said Dr. ...
(Date:2/23/2017)... ... 23, 2017 , ... The Greater Gift Initiative, Inc , (GGI) a ... Research . GGI's mission is to advance global health and highlight the greater good ... honor of each clinical trial volunteer. The vision of GGI is to serve as ...
Breaking Biology Technology:
(Date:2/22/2017)... Feb. 22, 2017 With the biometrics ... Research identifies four technologies that innovative and agile ... significant share in the changing competitive landscape: multifactor ... authentication.   "Companies can no longer ... security," says Dimitrios Pavlakis , Industry Analyst ...
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
Breaking Biology News(10 mins):